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This study sought to evaluate the association of 28 single nucleotide polymorphisms (SNPs) within 
NFKB and inflammasome pathway genes with the risk of rheumatoid arthritis (RA) and response to TNF 
inhibitors (TNFi). We conducted a case-control study in a European population of 1194 RA patients and 
1328 healthy controls. The association of potentially interesting markers was validated with data from 
the DANBIO (695 RA patients and 978 healthy controls) and DREAM (882 RA patients) registries. The 
meta-analysis of our data with those from the DANBIO registry confirmed that anti-citrullinated protein 
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antibodies (ACPA)-positive subjects carrying the NFKB2rs11574851T allele had a significantly increased risk 
of developing RA (PMeta_ACPA + = 0.0006) whereas no significant effect was found in ACPA-negative 
individuals (PMeta_ACPA− = 0.35). An ACPA-stratified haplotype analysis including both cohorts 
(n = 4210) confirmed that ACPA-positive subjects carrying the NFKB2tt haplotype had an increased 
risk of RA (OR = 1.39, P = 0.0042) whereas no effect was found in ACPA-negative subjects (OR = 1.04, 
P = 0.82). The meta-analysis of our data with those from the DANBIO and DREAM registries also 
revealed a suggestive association of the NFKB2rs1056890 SNP with larger changes in DAS28 (OR = 1.18, 
P = 0.007). Functional experiments showed that peripheral blood mononuclear cells from carriers of the 
NFKB2rs1005044C allele (in LD with the rs1056890, r2 = 1.00) showed increased production of IL10 after 
stimulation with LPS (P = 0.0026). These results provide first evidence of a role of the NFKB2 locus in 
modulating the risk of RA in an ACPA-dependent manner and suggest its implication in determining the 
response to TNFi. Additional studies are now warranted to further validate these findings.
Rheumatoid arthritis (RA) is a chronic inflammatory disease more frequently diagnosed in females than males, 
that has a prevalence of about 0.5–1%1. RA perpetuates and amplifies itself through a wide number of molecular 
mechanisms involving several immune cell types and multiple inflammatory mediators that are released from the 
damaged tissue2. Although the complexity of inflammatory pathways implicated in RA development and progres-
sion remains in part unknown, there are convincing evidences supporting the view that NFKB pathway and its 
connection with the NLRP3-inflammasome plays a pivotal role in the modulation of the expression of multiple 
inflammatory genes implicated in RA development3 and drug response or disease progression4.
Activated NFKB has been detected in the synovium of RA patients at both early and late stages of joint inflam-
mation5–8 and once NFKB is activated (for instance, through the interaction of antigen presenting cells and T 
cells), it triggers two major signaling pathways in the implicated cells: the canonical and the non-canonical NFKB 
pathway. Whereas the canonical pathway regulates the activation of NFKB1 p50, RELA and c-REL and leads to 
rapid but transient NFKB activation, the non-canonical NFKB pathway selectively activates p100-sequestered 
NFKB members (predominantly NFKB2 p52 and RELB) and produces a long-lasting signaling. Even though 
a cross-talk between the canonical and non-canonical NFKB pathways has been previously reported, the acti-
vation of the canonical NFKB pathway is generally associated with inflammation whereas the induction of the 
non-canonical NFKB pathway was linked to development processes9. In RA, it is well known that the acute acti-
vation of the canonical pathway on antigen presenting cells and T cells quickly leads to the production of a wide 
range of essential proinflammatory mediators including cytokines (TNFα, IL1α, IL1β, IL1RA, IL2, IL12p40 and 
IFNγ), chemokines (IL8, CXCL11), immunoreceptors (CD80, CD23, CD48, CD69, IL2R, TNFRs, and CCR5), 
cell adhesion molecules (ELAM-1, ICAM-1, VCAM-1 and P-selectin) and growth factors (GM-CSF, IGFBP2, 
and PDGFB) that often facilitate synovial hyperplasia by promoting cell proliferation and apoptosis inhibition of 
RA fibroblast-like synovial cells10. On the contrary, the activation of the non-canonical pathway involves a slow 
build-up of long-lasting signals that have been implicated in developmental processes including B-cell devel-
opment11, secondary lymphoid organ development12,13 and osteoclast differentiation14 but also development of 
myeloid-related CD4+CD8α− dendritic cells and macrophages15, key players in modulating immune responses 
in RA.
Besides the role of NFKB in the inflammatory process, recent evidences have shown that the 
NLRP3-inflammasome is a cytosolic multiprotein complex highly expressed in peripheral blood mononuclear 
cells of RA patients and in the synovial tissues of osteoarthritis patients. The NLRP3 inflammasome is capable 
of alerting immune system to the presence of tissue damage and to induce the processing of the IL1β, IL18 and 
IL33 pro-cytokines into biologically active proinflammatory mediators that drive cartilage destruction16. In addi-
tion, it has been reported that the presence of mutations in NLRP3-inflammasome-related proteins (CARD8 
and NLRP3) predispose to RA17,18 and that genetic variation in this pathway might also modulate inflammatory 
activity in early stages of the disease and thereby affect disease progression17,18.
Considering the aspects detailed above, but also previous studies suggesting that the NFKB- and 
NLRP3-inflammasome pathways are genetically determined19, we decided to conduct a case-control study to 
investigate whether 28 single nucleotide polymorphisms (SNPs) within the NFKB1, NFKB2, NFKBIB, IKBKB, 
GBP6, IRF4, NLRP3, REL, RELA, KLRC1, KLRK1 | KLRC4, LOC105376246 (ncRNA), TLR4, TLR5, TLR9, TLR10 
and TRAF1 | C5 genes influence the risk of developing RA and the response to TNF inhibitors (TNFi). In addi-
tion, we investigated the correlation of selected SNPs with steroid hormone levels and their role in modulating 
immune responses after stimulation of whole blood, peripheral mononuclear cells (PBMCs) and macrophages 
with lipopolysaccharide (LPS), phytohemagglutinin (PHA) and Pam3Cys.
Material and Methods
Discovery population. The discovery population consisted of 1194 RA patients and 1328 healthy con-
trols ascertained through the REPAIR consortium (Table 1). RA patients fulfilled the 1987 revised American 
College of Rheumatology (ACR)20 and the ACR/EULAR 2010 classification criteria21. The study followed the 
Declaration of Helsinki. Study participants were of European origin and gave their written informed consent 
to participate in the study, which was approved by the ethical review committee of participant institutions. The 
Ethics committee of each participant institution approved the study protocol: Virgen de las Nieves University 
Hospital (2012/89); Santa Maria Hospital-CHLN (CE 877/121.2012); University Clinical Hospital of Santiago 
de Compostela (2013/156). A detailed description of the discovery population has been reported elsewhere22–24.
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Response to anti-TNF medications. Six hundred and four RA patients treated with TNFi (adalimumab, 
etanercept, infliximab, golimumab or certolizumab) were included in the drug response analysis of the discovery 
population. The change in disease activity score (DAS28) at baseline and at 6 months of treatment with TNFi was 
calculated for each patient. Linear regression analysis adjusted for age and sex was used to determine the associ-
ation between selected SNPs and changes in DAS28. Subjects with missing values for DAS28 in any of these time 
points were not included in the analysis.
SNP selection and genotyping. NFKB- and inflammasome-related polymorphisms were selected on the 
basis of their potential functionality and linkage disequilibrium (LD) but also because of existing studies report-
ing their significant association with the risk of developing autoimmune and immune-related diseases or response 
to TNFi25–29. This strategy resulted in the selection of 28 genetic variants within the GBP6, IKBKB, IRF4, KLRC1, 
KLRK1, NFKB1, NFKB2, NFKBIB, NLRP3, REL, RELA, RELB, TLR4, TLR5, TLR9, TLR10 and TRAF1/C5 loci 
that were genotyped in the discovery population (Table 2). Genomic DNA was extracted from peripheral blood 
using the Qiagen Mini Kit (Qiagen, CA, USA) or from saliva using standard procedures. Genotyping was carried 
out using KASPar® assays (LGC Genomics, London, UK) in a 384-well plate format (Applied Biosystems, CA, 
USA) according to manufacturer’s instructions. Five percent of samples were included as duplicates to ensure 
high-quality genotyping.
Statistical analysis. The Hardy-Weinberg Equilibrium (HWE) test was performed in the control group by 
a standard observed-expected chi-square (χ2). Logistic and linear regression analyses adjusted for age, sex and 
country of origin were used to assess the main effects of the selected SNPs on RA risk and the response to TNFi 
respectively. Statistical power was estimated using Quanto software (http://hydra.usc.edu/gxe/). Correction for 
multiple testing was performed using the Meff method for SNPs genotyped across all populations30. The threshold 
used for the risk and drug response analyses was 0.0008 ([0.05/22 independent markersx3 inheritance models).
Linkage disequilibrium (LD) and haplotype analysis. We performed haplotype frequency estimation 
and haplotype association analysis adjusted for age, sex and country of origin using SNPstats31 and haplo.stats 
package in STATA. Haplotype frequencies were determined using the Expectation-maximization (EM) algo-
rithm. Haplotypes were reconstructed using SNPtool and Haploview and block structures were determined 
according to the method of Gabriel et al.32.
RA patient populations
Demographic 
characteristics
Discovery Population 
(n = 1194)
DREAM † Registry 
(n = 882)
DANBIO Registry 
(n = 695)
Age (years) 59.22 ± 12.97 54.63 ± 12.80 54.27 ± 13.30
Gender ratio (female/male) 4.01 (959/234) 2.07 (477/230) 2.80 (512/183)
Clinical assessment
RF positive patients* 764 (68.64) 534 (77.62) 221 (64.06)
ACPA positive patients* 643 (70.74) 151 (62.14) 390 (72.90)
DAS28 at baseline 5.74 ± 2.15 5.33 ± 1.26 4.77 ± 1.23
Disease duration (years) 17.60 ± 9.99 9.70 ± 9.57 7.89 ± 8.86
Treatments
csDMARDs at baseline
  Methotrexate (%) 798 (66.83) 463 (65.40) 514 (73.95)
  Leflunomide (%) 324 (27.14) ND ND
  Sulphasalazine (%) 149 (12.48) ND ND
First biologic agent
  Infliximab (%) 386 (32.33) 244 (34.46) 159 (22.88)
  Etanercept (%) 227 (19.01) 130 (18.36) 200 (28.78)
  Adalimumab (%) 191 (16.00) 334 (47.18) 173 (24.89)
  Golimumab (%) 17 (01.42) — 47 (06.76)
  Certolizumab (%) — — 72 (10.36)
  Rituximab (%) 13 (01.09) — 16 (02.30)
  Tocilizumab (%) 6 (00.50) — 19 (02.73)
  Anakinra (%) — — 2 (00.29)
  Others (%) 14 (01.17) — 7 (01.01)
Table 1. Demographic and clinical characteristics of RA patients. Data are means ± standard deviation or n 
(%). Abbreviations: RF, rheumatoid factor; ACPA: anti-cyclic citrullinated peptide antibodies; DAS28, disease 
activity score; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs. ND, not determined 
(unknown). †Clinical data for 708 RA patients that were available for genotyping. *RF was available for 1113, 
688 and 345 patients in the discovery, DREAM and DANBIO populations, respectively. *ACPA was available 
for 908, 127 and 535 patients in the discovery, DREAM and DANBIO populations, respectively.
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Replication populations and meta-analyses for RA risk and drug response. For replication pur-
poses, we genotyped the most promising SNPs associated with RA risk in a cohort of 695 Danish RA patients and 
978 healthy controls33. Clinical data from RA patients were collected through the DANBIO registry (The National 
Gene Chr. dbSNP rs#
Nucleotide 
substitution
Effect-
allele Location
Reported associations with autoimmune 
diseases, drug response and/or potential 
functional role
GBP6 1 rs928655 A/G A Intronic Associated with etanercept response in moderate-to-severe plaque psoriasis47
IKBKB 8 rs11986055 A/C A Intronic
IRF4 6 rs1050975 A/G A 3′-UTR/ncRNA
IRF4 6 rs12203592 C/T T Intronic Correlated with white blood cell count48
IRF4 6 rs1877175 C/T T 3′-UTR/ncRNA
IRF4 6 rs7768807 T/C T 3′-UTR/ncRNA
KLRC1 12 rs7301582 C/T T Intronic Associated with response to anti-TNF therapy in RA patients49
KLRK1 | KLRC4 12 rs1049174 C/G C 3′UTR/Intronic Associated with response to anti-TNF therapy in RA patients50
KLRK1 | KLRC4 12 rs1154831 A/C A Intronic/Near gene Lack of association with response to anti-TNF therapy50
KLRK1 | KLRC4 12 rs2255336 A/G A Thre72Ala
Correlation with blood NKG2D type II 
integral membrane protein levels51 and 
associated with response to anti-TNF 
therapy in RA patients50; Associated with a 
decreased risk of Lupus erythematosus52,53
LOC105376246 9 rs2722824 A/C A Near gene
NFKB1 4 rs4648110 A/T A Intronic
NFKB2 10 rs11574851 C/T T Asn698Asn
NFKB2 10 rs12769316 C/T T Near gene
NFKB2 | PSD 10 rs1056890 C/T T Near gene/3′-UTR
NFKBIB 19 rs3136645 C/T C ncRNA Associated with response to anti-TNF drugs in RA patients25
NLRP3 1 rs4612666 C/T T Intronic Associated with response to anti-TNF drugs in RA patients42
REL 2 rs13031237 G/T T Intronic
Overall association with the risk of RA at 
GWAS level29,54,55. Association with RA in 
ACPA-positive individuals at GWAS level55; 
Association with early-onset psoriasis56 and 
autoimmune diseases57 in large candidate 
gene association studies
REL 2 rs842647 A/G A Intronic Associated with susceptibility to Behcet’s disease58
REL 2 rs13017599 A/G A Near gene
Associated with RA and psoriatic arthritis 
at GWAS level29,59 and in a candidate gene 
association study60
RELA 11 rs11820062 C/T T Intronic Eosinophil counts48
RELA 11 rs2306365 A/G A Intronic
RELA 11 rs7119750 C/T T Intronic
TLR10 4 rs11096957 A/C A Asn241His
Associated with hip osteoarthritis61,62 and 
effectiveness of biologics for psoriasis 
treatment at GWAS level63
TLR4 9 rs4986791 C/T T Thr399Ile
TLR4: lymphocyte 96 antigen complex 
level51; Associated with RA risk and response 
to anti-TNF drugs64; Associated with risk of 
developing inflammatory bowel disease65
TLR5 1 rs5744174 C/T C Phe616Leu
Associated with response to anti-TNF drugs 
in RA patients27; Associated with the risk of 
Crohns disease66 and response to anti-TNF 
treatment67; Associated with response 
to ustekinumab treatment in psoriasis 
patients68
TLR9 | | TWF2 3 rs187084 G/A T Near gene
Associated with psoriatic arthritis risk69, hip 
and knee osteoarthritis70,71, SLE72 and IBD73; 
associated with the risk of autoimmune 
thyroid disease74; response to anti-TNF 
therapy in patients with RA64 and IBD75
TRAF1 | | C5 9 rs3761847 A/G A Near gene Associated with RA at GWAS level54,76
Table 2. Selected SNPs within NFKB-related genes. Abbreviations: SNP, single nucleotide polymorphism; 
UTR, untranslated region; ncRNA, non-coding Ribonucleic acid. Risk alleles were select according to available 
GWAS data in order to make possible a meta-analysis of the discovery and replication cohorts.
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Danish Registry for Biological Treatment of Rheumatic Diseases)34 and DNA samples were obtained from periph-
eral blood collected at the Statens Serum Institut (Copenhagen, Denmark), which routinely perform screening 
for tuberculosis before treatment with biological treatments. Healthy blood donors were recruited in Viborg and 
Sønderborg (Denmark). In order to replicate the most interesting associations with response to TNFi, we also 
used genetic data from a genome-wide association study (GWAS) on drug response conducted in 882 Dutch RA 
patients from the DREAM (Dutch RhEumatoid Arthritis Monitoring) registry. Imputed SNPs reporting poten-
tially interesting overall or ACPA-specific associations with RA risk or drug response were genotyped in a subset 
of 708 patients. To further validate our results, we also genotyped the most interesting markers associated with 
drug response in 555 RA patients from the DANBIO registry that were treated with TNFi. A total of 2107 patients 
were treated with anti-TNF. Demographic and clinical details of the 3 cohorts are included in Supplementary 
Table 1. The study was approved by the Institutional review board of the Radboud university medical centre and 
by the Regional Ethics Committee of Central Denmark Region (M-20100153 and S-20120113). All patients pro-
vided written informed consent and clinical information was prospectively gathered from the medical records.
To test for genetic association, we conducted a meta-analysis of the discovery data with those from the 2 
European registries and the I2 statistic was used to assess statistical heterogeneity between studies. The pooled OR 
was computed using the random-effect model.
Functional analysis of the NFKB and inflammasome-related variants. Cytokine stimulation 
experiments were conducted in the 500 Functional Genomics (500FG) cohort from the Human Functional 
Genomics Project (HFGP; http://www.humanfunctionalgenomics.org/), which was designed to determine the 
influence of genomic variation on the variability of immune responses. The HFGP study was approved by the 
Arnhem-Nijmegen Ethical Committee (no. 42561.091.12) and biological specimens (venous blood) were col-
lected after informed consent was obtained. We assessed whether any of the 28 NFKB and inflammasome-related 
SNPs correlated with cytokine levels (TNFα, IFNγ, IL1β, IL1RA, IL6, IL8, IL10, IL17, and IL22) after the stim-
ulation of whole blood, peripheral blood mononuclear cells (PBMCs) or monocyte-derived macrophages from 
408 healthy subjects with LPS (1 or 100 ng/ml), PHA (10 μg/ml), and Pam3Cys (10 μg/ml). After log transforma-
tion, linear regression analyses adjusted for age and sex were used to determine the correlation of selected SNPs 
with cytokine expression quantitative trait loci (cQTLs). All analyses were performed using R software (http://
www.r-project.org/). In order to account for multiple comparisons, we used a significant threshold of 0.00025, i.e. 
0.05/(22 independent SNPs × 9 cytokines).
Details on PBMCs isolation, macrophage differentiation and stimulation assays have been reported else-
where35–37. Briefly, PBMCs were washed twice in saline and suspended in medium (RPMI 1640) supplemented 
with gentamicin (10 mg/mL), L-glutamine (10 mM) and pyruvate (10 mM). PBMC stimulations were performed 
with 5 × 105 cells/well in round-bottom 96-wells plates (Greiner) for 24 hours in the presence of 10% human pool 
serum at 37 °C and 5% CO2. Supernatants were collected and stored in −20 °C until used for ELISA. LPS (100 ng/
ml), PHA (10 μg/ml) and Pam3Cys (10 μg/ml) were used as stimulators for 24 or 48 hours. Whole blood stimula-
tion experiments were conducted using 100 μl of heparin blood that was added to a 48 well plate and subsequently 
stimulated with 400 μl of LPS and PHA (final volume 500 ul) for 48 hours at 37 °C and 5% CO2. Supernatants were 
collected and stored in −20 °C until used for ELISA. Concentrations of human TNFα, IFNγ, IL1β, IL1RA, IL6, 
IL8, IL10, IL17, and IL22 were determined using specific commercial ELISA kits (PeliKine Compact, Amsterdam, 
or R&D Systems), in accordance with the manufacturer’s instructions.
Once we examined the correlation of NFKB and inflammasome-related polymorphisms with cytokine levels 
in our functional experiments, we also used the HaploReg SNP annotation tool (http://www.broadinstitute.org/
mammals/haploreg/haploreg.php) to further investigate the functional consequences of each specific variant. We 
also assessed whether any of the potentially interesting markers correlated with mRNA expression levels of their 
respective genes using data from GTex portal (www.gtexportal.org/home/).
Correlation between steroid hormone levels and NFKB- and inflammasome-related SNPs. We 
also measured serum levels of seven steroid hormones (androstenedione, cortisol, 11-deoxy-cortisol, 17-hydroxy 
progesterone, progesterone, testosterone and 25 hydroxy vitamin D3) in the 500FG cohort, which includes 531 
healthy subjects. Steroid hormones were analyzed by Liquid Chromatography Tandem-Mass Spectrometry 
(LCMSMS) after protein precipitation and solid-phase extraction as described in Ter Horst et al.37 (see also 
Supplementary Material). Hormone levels and genotyping data were available for a total of 406 subjects.
After log-transform, correlation between steroid hormone levels and NFKB- and inflammasome-related SNPs 
was evaluated by linear regression analysis adjusted for age and sex. In order to avoid a possible bias, we excluded 
those subjects that were using oral contraceptives or those subjects in which this information was not known 
from the analysis. A total of 379 healthy subjects (107 women and 272 men) were finally available for analysis. A 
Bonferroni significance threshold was set to 0.00033 considering the number of independent SNPs tested (n = 22) 
and the number of hormones determined (n = 7).
Results
This study was conducted in a discovery population comprised of 1194 RA patients and 1328 healthy controls. RA 
patients were slightly older than controls (59.22 ± 12.97 vs. 52.67 ± 8.99) and showed an increased female/male 
ratio compared to healthy controls (4.10 [959/234] vs. 1.39 [773/555]. Sixty percent of the RA patients presented 
positive values of anti-citrullinated protein antibodies (ACPA) and the median disease duration was of 17.60 
years and the disease activity score 28 (DAS28) calculated at patient recruitment was of 5.74 (Table 1).
Association of selected SNPs with RA risk. All SNPs were in Hardy-Weinberg equilibrium in the con-
trol group (P > 0.001). Logistic regression analysis adjusted for age, sex and country of origin showed that carriers 
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of the NLRP3rs4612666T allele or the IRF4rs1050975A/A and NFKB2rs12769316T/T genotypes had an increased risk of devel-
oping RA at nominal level of P ≤ 0.05 (ORDom = 1.25, 95%CI 1.05–1.49, P = 0.013; ORRec = 1.30, 95%CI 1.04–
1.62, P = 0.019; and ORRec = 1.70, 95%CI 1.04–2.78, P = 0.034; Table 3). Interestingly, an ACPA-stratified analysis 
revealed that ACPA-positive subjects carrying the NFKB1rs4648110A/A genotype or the NFKB2rs11574851T allele had 
a significantly increased risk of developing RA whereas a non-significant effect was found in ACPA-negative 
patients (ORRec-ACPA+ = 1.65, 95%CI 1.04–2.63, P = 0.031 vs. ORRec-ACPA− = 0.86, 95%CI 0.39–1.90, P = 0.90 and 
per-allele ORACPA+ = 1.39, 95%CI 1.06–1.83, P = 0.017 and per-allele ORACPA− = 1.02, 95%CI 0.68–1.52, P = 0.93; 
Table 3). On the other hand, we found that seronegative subjects carrying the KLRCrs7301582T or KLRK1rs1049174C 
alleles showed a significantly increased risk of developing RA whereas no effect was detected in ACPA-positive 
individuals (ORDom-ACPA− = 1.56, 95%CI 1.18–2.09, P = 0.003 vs. ORDom-ACPA+ = 1.05, 95%CI 0.84–1.30, P = 0.67 
and ORDom-ACPA− = 1.38, 95%CI 1.03–1.84, P = 0.031 vs. ORDom-ACPA+ = 1.09, 95%CI 0.88–1.35, P = 0.42).
Although none of the above-reported associations survived after correction for multiple testing, we attempted 
to replicate them through meta-analysis of the discovery data with those from the DANBIO registry. The 
meta-analysis of these two populations, which included 4194 subjects (1888 RA patients and 2306 healthy con-
trols), confirmed that carriers of the NFKB2rs12769316T/T genotype had an increased risk of developing RA when 
compared with those carrying the C allele (ORMeta = 1.78, 95%CI 1.21–2.63, P = 0.0037, I2 = 0.0%, PHet = 0.76; 
Supplementary Table 2). In addition, although the association was only significant at nominal level (P < 0.05), we 
also found that carriers of the NFKB2rs11574851T allele also had an increased risk of developing RA (ORMeta = 1.29, 
95%CI 1.02–1.64, P = 0.035, PHet = 0.27). Given that no population stratification was detected (Supplementary 
Table 3), these findings suggested that the effect attributed to the NFKB2 locus on the risk of RA was likely true 
and might depend on a specific haplotype rather than single SNPs. Following this hypothesis, we performed an 
overall haplotype analysis that revealed that carriers of the NFKB2TC haplotype (including the NFKB2rs11574851T 
allele) had a significantly increased risk of developing RA (OR = 2.21, 95%CI 1.37–3.56, P = 0.0011). Although 
Gene SNP ID Chr.
Effect 
allele
Overall RA (n = 2521) 
1193 RA/1328 Controls
ACPA+ RA patients 
(n = 1971) 643 RA/1328 
Controls
ACPA- RA patients 
(n = 1593) 265 RA/1328 
Controls
OR (95% CI)∂ P OR (95% CI)∂ P OR (95% CI)∂ P
GBP6 rs928655 1 A 0.94 (0.81–1.08) 0.37 0.88 (0.74–1.04) 0.14 1.08 (0.84–1.38) 0.54
IKBKB rs11986055 8 A 0.93 (0.71–1.21) 0.59 1.15 (0.83–1.62) 0.40 0.99 (0.65–1.53) 0.98
IRF4 rs1050975 6 A 1.30 (1.04–1.62)§ 0.019 1.51 (1.14–1.99)§ 0.003 1.30 (0.91–1.86)§ 0.15
IRF4 rs12203592 6 T 0.97 (0.81–1.18) 0.79 0.99 (0.78–1.24) 0.92 0.83 (0.60–1.17) 0.29
IRF4 rs1877175 6 T 1.00 (0.86–1.16) 0.98 0.97 (0.80–1.16) 0.70 1.04 (0.82–1.32) 0.74
IRF4 rs7768807 6 T 0.95 (0.83–1.10) 0.51 0.93 (0.78–1.09) 0.36 1.03 (0.82–1.30) 0.78
KLRC1 rs7301582 12 T 1.15 (1.00–1.34)† 0.050 1.05 (0.84–1.30)† 0.67 1.56 (1.18–2.09)† 0.002
KLRK1 | KLRC4 rs1049174 12 C 1.18 (0.99–1.41)† 0.068 1.09 (0.88–1.35)† 0.42 1.38 (1.03–1.84)† 0.031
KLRK1 | KLRC4 rs1154831 12 A 1.00 (0.86–1.16) 0.99 1.05 (0.88–1.26) 0.59 0.92 (0.71–1.17) 0.48
KLRK1 | KLRC4 rs2255336 12 A 1.10 (0.94–1.27) 0.22 1.04 (0.87–1.25) 0.68 1.33 (0.99–1.77)† 0.055
LOC105376246 rs2722824 9 A 0.96 (0.83–1.10) 0.53 0.93 (0.79–1.10) 0.41 1.08 (0.86–1.36) 0.50
NFKB1 rs4648110 4 A 1.28 (0.85–1.93)§ 0.23 1.65 (1.04–2.63)§ 0.031 0.86 (0.39–1.90)§ 0.90
NFKB2 rs11574851 10 T 1.17 (0.93–1.48) 0.19 1.39 (1.06–1.83) 0.017 1.02 (0.68–1.52) 0.93
NFKB2 rs12769316 10 T 1.70 (1.04–2.78)§ 0.034 1.70 (0.95–3.06)§ 0.077 2.53 (1.24–5.14)§ 0.011
NFKB2 | PSD rs1056890 10 T 0.96 (0.84–1.09) 0.54 0.95 (0.81–1.12) 0.56 1.01 (0.82–1.25) 0.90
NFKBIB rs3136645 19 C 1.07 (0.91–1.24) 0.42 1.15 (0.95–1.38) 0.14 0.81 (0.62–1.04) 0.10
NLRP3 rs4612666 1 T 1.25 (1.05–1.49)† 0.013 1.29 (1.04–1.60)† 0.020 1.18 (0.89–1.56)† 0.26
REL rs13031237 2 T 1.16 (0.91–1.48)† 0.24 1.15 (0.85–1.53)§ 0.36 1.48 (1.02–2.15)§ 0.040
REL rs842647 2 A 1.08 (0.94–1.24) 0.30 1.10 (0.93–1.31) 0.27 1.05 (0.83–1.33) 0.68
REL rs13017599 2 A 1.06 (0.93–1.20) 0.40 1.04 (0.89–1.21) 0.64 1.17 (0.95–1.43) 0.13
RELA rs11820062 11 T 0.93 (0.82–1.06) 0.29 0.91 (0.78–1.05) 0.20 1.07 (0.88–1.31) 0.49
RELA rs2306365 11 A 1.07 (0.89–1.29) 0.48 1.02 (0.81–1.28) 0.86 1.16 (0.86–1.57) 0.32
RELA rs7119750 11 T 1.09 (0.91–1.32) 0.34 1.04 (0.82–1.30) 0.76 1.24 (0.93–1.65) 0.15
TLR10 rs11096957 4 A 1.12 (0.99–1.27) 0.066 1.13 (0.98–1.32) 0.10 1.08 (0.89–1.33) 0.43
TLR4 rs4986791 9 T 1.17 (0.89–1.54) 0.25 1.15 (0.83–1.60) 0.40 1.00 (0.63–1.58) 0.99
TLR5 rs5744174 1 C 0.99 (0.87–1.13) 0.86 1.03 (0.88–1.20) 0.75 0.89 (0.72–1.10) 0.27
TLR9 | | TWF2 rs187084 3 T 0.97 (0.85–1.10) 0.61 0.93 (0.80–1.09) 0.39 1.02 (0.83–1.25) 0.88
TRAF1 | | C5 rs3761847 9 A 0.97 (0.85–1.10) 0.61 1.00 (0.86–1.17) 0.99 0.91 (0.74–1.13) 0.39
Table 3. Overall and ACPA-specific associations of NFKB-related polymorphisms and risk of developing RA 
(discovery population). Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence 
interval. ∂Estimates calculated according to an additive model of inheritance and adjusted for age, sex and 
country of origin. †Estimates calculated according to a dominant model of inheritance and adjusted for age, sex 
and country of origin. §Estimates calculated according to a recessive model of inheritance and adjusted for age, 
sex and country of origin. P ≤ 0.05 in bold. Data on anti-ccp was missing in 285 patients.
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this association did not survive multiple testing correction, it pointed to a role of the NFKB2rs11574851 SNP to confer 
risk to RA development.
Most importantly, an ACPA-stratified meta-analysis of our data with those from the DANBIO registry also 
revealed that each copy of the NFKB2rs11574851T allele conferred an additive risk of developing RA in ACPA-positive 
subjects (ORMeta = 1.48, 95%CI 1.18–1.86, P = 0.0006) that was not detected in ACPA-negative individuals 
(Table 4 and Fig. 1). Of note, the association of the NFKB2rs11574851 SNP with an increased risk of RA remained 
significant after correction for multiple testing and the direction of the effect was consistent with no significant 
heterogeneity between cohorts (PHet = 0.40; Fig. 1). The ACPA-stratified meta-analysis of both populations also 
showed an increased risk of RA in ACPA-positive and ACPA-negative subjects carrying the NFKB2rs12769316T/T 
genotype (P = 0.013 and P = 0.004; Table 4 and Supplementary Table 4). Even though none of the associations of 
the NFKB2rs12769316T/T genotype with RA remained significant after correction for multiple testing, these findings 
supported the notion of a relevant role of the NFKB2 locus in modulating the RA risk. In order to further confirm 
this hypothesis, we decided to evaluate whether there was an ACPA-specific haplotype that could influence the 
risk of developing RA. Interestingly, the ACPA-stratified haplotype analysis including both the discovery and 
DANBIO cohorts also confirmed that ACPA-positive subjects carrying the NFKB2TT haplotype (including the 
NFKB2rs11574851T risk allele) had a significantly increased risk of RA (ORHaplotype-ACPA+ = 1.39, 95%CI 1.11–1.74, 
P = 0.0042) whereas no effect was detected in ACPA-negative individuals (ORHaplotype-ACPA− = 1.04, 95%CI 0.75–
1.44, P = 0.82; Table 5). These results again pointed to an ACPA-specific effect of the NFKB2 locus to modulate 
the risk of RA. No additional overall or ACPA-specific associations were confirmed in the meta-analysis of both 
cohorts.
On the basis of the effect found for the NFKB2rs11574851 or NFKB2rs12769316 SNPs on the risk of developing RA, 
we decided to analyse whether these SNPs might exert their biological function directly through the modulation 
of NFKB2-mediated immune responses or indirectly through the regulation of steroid hormone levels. To do 
Gene SNP ID Chr.
Effect 
allele
Discovery population 
ACPA+ RA vs. controls 
(n = 1971)
Replication DANBIO 
Registry ACPA+ RA vs. 
controls (n = 1741)
Meta-analysis ACPA+ RA vs. controls 
(n = 3712)
OR (95% CI)∂ P OR (95% CI)∂ P OR (95% CI)∂ P I2
GBP6 rs928655 1 A 0.88 (0.74–1.04) 0.14 1.24 (0.97–1.58) 0.079 1.03 (0.74–1.44) 0.85 0.024
IKBKB rs11986055 8 A 1.15 (0.83–1.62) 0.40 — — — — —
IRF4 rs1050975 6 A 1.51 (1.14–1.99)§ 0.003 0.93 (0.65–1.32)§ 0.68 1.12 (0.74–1.93)§ 0.45 0.035
IRF4 rs12203592 6 T 0.99 (0.78–1.24) 0.92 — — — — —
IRF4 rs1877175 6 T 0.86 (0.75–1.01) 0.065 1.06 (0.84–1.33) 0.61 0.93 (0.77–1.15) 0.52 0.13
IRF4 rs7768807 6 T 0.93 (0.78–1.09) 0.36 — — — — —
KLRC1 rs7301582 12 T 1.15 (0.97–1.37) 0.096 0.85 (0.67–1.08) 0.19 1.00 (0.74–1.34) 1.00 0.044
KLRK1 | KLRC4 rs1049174 12 C 1.06 (0.90–1.25) 0.45 0.95 (0.76–1.19) 0.66 — — —
KLRK1 | KLRC4 rs1154831 12 A 1.05 (0.88–1.26) 0.59 — — — — —
KLRK1 | KLRC4 rs2255336 12 A 1.04 (0.87–1.25) 0.68 — — — — —
LOC105376246 rs2722824 9 A 0.93 (0.79–1.10) 0.41 — — — — —
NFKB1 rs4648110 4 A 1.16 (0.97–1.39) 0.11 — — — — —
NFKB2 rs11574851 10 T 1.39 (1.06–1.83) 0.017 1.72 (1.14–2.59) 0.009 1.48 (1.18–1.86) 0.0006 0.40
NFKB2 rs12769316 10 T 1.70 (0.95–3.06)§ 0.077 1.91 (0.93–3.92)§ 0.080 1.78 (1.13–2.80)§ 0.013 0.81
NFKB2 | PSD rs1056890 10 T 0.95 (0.81–1.12) 0.56 — — — — —
NFKBIB rs3136645 19 C 1.15 (0.95–1.38) 0.14 — — — — —
NLRP3 rs4612666 1 T 1.29 (1.04–1.60)† 0.020 1.06 (0.81–1.39)† 0.68 1.19 (0.99–1.44)† 0.072 0.27
REL rs13031237 2 T 1.15 (0.85–1.53)§ 0.36 1.15 (0.78–1.70)§ 0.47 1.15 (0.91–1.45)§ 0.24 1.00
REL rs842647 2 A 1.10 (0.93–1.31) 0.27 — — — — —
REL rs13017599 2 A 1.04 (0.89–1.21) 0.64 1.02 (0.83–1.25) 0.86 1.03 (0.91–1.17) 0.61 0.88
RELA rs11820062 11 T 0.91 (0.78–1.05) 0.20 — — — — —
RELA rs2306365 11 A 1.02 (0.81–1.28) 0.86 — — — — —
RELA rs7119750 11 T 1.04 (0.82–1.30) 0.76 — — — — —
TLR10 rs11096957 4 A 1.13 (0.98–1.32) 0.10 0.75 (0.60–0.93) 0.010 0.93 (0.62–1.39) 0.72 0.002
TLR4 rs4986791 9 T 1.15 (0.83–1.60) 0.40 — — — — —
TLR5 rs5744174 1 C 1.03 (0.88–1.20) 0.75 — — — — —
TLR9 | | TWF2 rs187084 3 T 0.93 (0.80–1.09) 0.39 — — — — —
TRAF1 | | C5 rs3761847 9 A 1.00 (0.86–1.17) 0.99 — — — — —
Table 4. Meta-analysis for the association of NFKB- and inflammosome-related polymorphisms and RA risk in 
ACPA+ patients. Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval. 
A random effect model was assumed for the meta-analysis of both cohorts. ∂Estimates calculated according to 
an additive model of inheritance and adjusted for age and sex. †Estimates calculated according to a dominant 
model of inheritance and adjusted for age and sex. §Estimates calculated according to a recessive model of 
inheritance and adjusted for age and sex. P < 0.05 in boldface.
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that we evaluated if there were any correlation between the NFKB2rs11574851 and NFKB2rs12769316 SNPs and levels 
of 9 cytokines (TNFα, IFNγ, IL1β, IL1RA, IL6, IL8, IL10, IL17, and IL22) after stimulation of whole blood, 
PBMCs or macrophages with LPS, PHA or Pam3Cys in a cohort of 408 healthy subjects. Although our func-
tional experiments were well powered, we did not find any significant correlation between the NFKB2rs11574851 and 
NFKB2rs12769316 SNPs and cytokine or steroid hormone levels (data not shown). Although these results might sug-
gest no impact of the NFKB2 variants in modulating immune responses, it is important to mention that we could 
not evaluate whether the effect of the NFKB2rs11574851 and NFKB2rs12769316 SNPs on the modulation of immune 
responses could be dependent on ACPA status as the genetic analyses indicate.
Association of selected SNPs with the response to anti-TNF drugs. When we evaluated the effect of 
any of the selected SNPs on the response to TNFi (defined as a change in DAS28 after 6 months of treatment), we 
found a significant effect of the NFKB2rs1056890 SNP to modulate the response to TNFi at nominal level (P < 0.05). 
Thus, each copy of the NFkB2rs1056890T allele additively increased the drop in DAS28 by 22% after the treatment 
with TNFi (per-allele OR = 1.22, 95%CI 1.03–1.44, P = 0.025; Table 6). Importantly, when we attempted to repli-
cate this association through a well-powered meta-analysis of our data from the discovery population with those 
from the DREAM and DANBIO registries (n = 2107), we could confirm that carriers of the NFKB2rs1056890T allele 
showed a significantly higher improvement in DAS28 after treatment with TNFi (ORMeta = 1.18, 95%CI 1.05–1.33, 
P = 0.0077, I2 = 51.7%, PHet = 0.13; Fig. 2A). Although this association did not remain significant after correction 
for multiple testing and therefore need to be further validated, this finding suggested that the NFKB2rs1056890 SNP 
might modulate the response to anti-TNF drugs through the regulation of the NFKB2-related immune responses.
In order to test this hypothesis, we assessed whether the NFKB2rs1056890 SNP was associated with cytokine and 
steroid hormone levels in the HFGP cohort. Although this SNP was not included in the genome-wide associa-
tion data available from the HFGP cohort, we could evaluate the association of this marker with cytokine and 
steroid hormone levels through the analysis of neighbouring SNPs in strong LD with it. Our stimulation experi-
ments showed that PBMCs from carriers of the NFKB2rs1005044C allele (in complete LD with the rs1056890T allele, 
r2 = 1.00) showed an increased production of IL10 after stimulation of PBMCs with LPS for 24 h (P = 0.0025; 
Fig. 2B). The analysis of additional neighbouring SNPs belonging to the same LD block allowed us to confirm the 
association of the rs1056890T allele with increased levels of IL10 (Supplementary Table 5). Although the associ-
ation of the NFKB2rs1056890 SNP with a better response to TNFi and its correlation with higher levels of IL10 did 
not remain statistically significant after correction for multiple testing, altogether these findings point to a role 
of this marker in determining the response to TNFi likely through the modulation of IL10-mediated immune 
responses. No significant association of the NFKB2rs1056890 SNP with response to TNFi was observed when associ-
ation analysis was stratified by ACPA, which dismissed the implication of ACPA in the functional effect attributed 
to this polymorphism. We did not find correlation of any of the NFKB2 SNPs with steroid hormone levels (data 
not shown), which also ruled out the implication of steroid hormones in the modulation of the IL10-mediated 
immune responses.
Discussion
Our data provided, for the first time, evidence that NFKB2 locus might modulate the risk of RA. The meta-analysis 
of the data obtained in the discovery population with those from the DANBIO cohort showed a potentially inter-
esting overall association of the NFKB2rs11574851 SNP with the risk of RA that was further confirmed in an overall 
haplotype analysis. Most importantly, we found that the effect attributed to the NFKB2 locus on RA risk depended 
on the ACPA status. An ACPA-stratified meta-analysis of the discovery and DANBIO populations including 3712 
subjects revealed that ACPA-positive subjects carrying the NFKB2rs11574851T allele had a significantly increased 
risk of developing RA whereas no effect was detected in ACPA-negative individuals. Of note, the association of 
the NFKB2rs11574851T allele with an increased risk of RA in ACPA-positive subjects remained significant even after 
correction for multiple testing and was further confirmed in an ACPA-stratified haplotype analysis that showed 
that the presence of the NFKB2rs11574851T allele was driving the effect of the NFKB2TA haplotype on the risk of RA 
in ACPA positive subjects but not in ACPA-negative individuals.
The NFKB2 gene is located on chromosome 10q24 and it encodes for a subunit of the NFKB complex (p100/
p52) that is expressed in multiple immune cells and modulates the inflammation. Other important processes 
involved in the RA pathology such as Th1 immune responses, activation, abnormal apoptosis and osteoclast 
differentiation and proliferation10 are also impacted. It is broadly known that RA arises as a consequence of 
Figure 1. Association of the NFKB2rs11574851 SNP with the risk of RA in ACPA-positive patients. Association 
estimates according a random effect model. P = 0.0006.
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the interaction between genetic and environmental factors and that the NFKB pathway plays a central role in 
determining the onset of the disease and its progression. In addition, it has been reported that the genetic and 
environmental factors that predispose to RA development are substantially different between ACPA-positive 
and ACPA-negative subjects. Recent studies have demonstrated, for instance, that the effect attributed to the two 
major genetic risk factors for RA (shared epitope of the HLADRB1 and a SNP on the PTPN22 gene) is clearly 
dependent on the ACPA status having a more evident effect in ACPA-positive subjects than in those lacking 
of these antibodies38. Furthermore, recent GWAS studies have reported the existence of a completely different 
genetic component or even a gene-smoking interaction pattern between ACPA-positive and ACPA-negative 
patients, again suggesting a relevant role of ACPA in determining the onset of the disease39,40. However, up to 
now, little is known about the effect of ACPA on the control of the NFKB pathway. Interestingly, recent inves-
tigations have demonstrated that the treatment of PBMCs-derived macrophages with ACPA induced the acti-
vation of the NFKB pathway and subsequently the induction of the NLRP3-inflammasome and the production 
of pro-inflammatory cytokines41. Mechanistically, it was demonstrated that ACPA induces the activation of the 
NFKB pathway through the induction of the interaction between CD147 and integrin β1 or ATGB1, which in turn 
activates the downstream Akt/NFKB signalling pathway, resulting in the upregulation of NLRP3 and pro-IL-1β 
expression and further NLRP3 inflammasome activation41. Considering these interesting findings, we decided to 
assess in the HFGP cohort if there was any correlation between the NFKB2 SNPs and pro- and anti-inflammatory 
cytokine production after stimulation of whole blood, PBMCs or monocyte-derived macrophages with LPS, PHA 
or Pam3Cys. We also analysed whether NFKB2 variants could indirectly affect immune responses through the 
modulation of steroid hormone levels. Despite the use of a large cohort of healthy subjects from the HFGP cohort, 
we could not find any significant correlation between the NFKB2rs11574851 and NFKB2rs12769316 SNPs and cytokine 
or steroid hormone levels. Although these results suggested that these variants might not exert their effect on 
RA risk through the modulation of NFKB2- or steroid hormone-mediated immune responses, we could not rule 
out the possibility of a true effect of these variants on the immune response as their effect might depend on the 
presence of ACPA (as suggested by our genetic data) or even specific haplotypes. In line with this hypothesis, in 
silico analysis using Haploreg data showed that the NFKB2rs11574851 and NFKB2rs12769316 SNPs mapped among his-
tone marks in multiple primary T helper naïve and memory cells and primary B cells from peripheral blood and 
they were predicted to act as enhancers in T helper memory cells and to change motifs for Po6fu1, AP-4, CEBPB, 
Mef2 and RP58. Even though these data supported the idea of a role of NFKB2 variants in modulating immune 
responses, we think that additional experiments are still needed to determine whether ACPA or specific haplo-
types are factors involved in modulating the effect of the NFKB2 locus on the risk of RA.
Besides the role of the NFKB2 locus in determining the risk of RA, this study also showed a noticeable impact 
of the NFKB2 gene in the modulation of the response to TNFi. In particular, the meta-analysis of the discovery 
population with data from the DREAM and DANBIO registries, including 2107 RA patients, showed that car-
riers of the NFKB2rs1056890T allele had an improvement in DAS28 after treatment with TNFi. We found that the 
direction of the effect of the NFKB2rs1056890 SNP on drug response was consistent across populations and that the 
effect was statistically significant in 2 of the 3 populations analysed. Although at this point it tempting to speculate 
that this SNP constitutes a biomarker for good response to TNFi in RA patients that might help to design more 
individualized treatment strategies, the association did not remain significant after correction for multiple testing 
and, therefore, need to be confirmed in independent populations. Mechanistically, we found that the presence 
of neighbouring genetic markers in strong LD with the NFKB2rs1056890 SNP were associated with increased levels 
of IL10, suggesting that the NFKB2 locus might be implicated in modulating IL10-mediated immune responses. 
Although the association of the NFKB2rs1056890 SNP with IL10 levels neither survive correction for multiple test-
ing, our results were in agreement with previous studies demonstrating that NFKB2 unlikely NFKB1 is implicated 
in the control of antigen presenting cell function and not in the activation of T and B cells. Likewise, recent studies 
have also identified genetic polymorphisms within the NFKB pathway as genetic biomarkers for response to TNFi 
in RA42 but also other autoimmune diseases42, which further supported our hypothesis suggesting a key role of 
the NFKB2 gene in modulating the response to TNFi. In addition, in silico tools such as Regulome showed that 
the rs1056890 SNP has a score of 4, which means that this polymorphism could affect transcription factor affinity 
and DNase peak43. Using haploreg it was also suggested that the NFKB2rs1056890 SNP might play a role in mod-
ulating immune responses as it mapped among histone marks in primary T helper naïve and T helper memory 
cells, T regulatory and primary NK cells and it was predicted to alter binding motifs for NRSF, Sin3Ak-20 and 
PLAG1. These transcription factors have been implicated in bone-related diseases44 and their activation results 
in up-regulation of multiple target genes including immune-related genes such as macrophage colony stimulator 
factor (MCSF) and insulin growth factor (IGF)-2.
NFKB2 rs11574851 rs12769316 99999 Freq
RA patients 
(n = 4210) OR 
(95% CI) P Freq
ACPA-positive 
patients (n = 3117) 
OR (95% CI) P Freq
ACPA-negative 
patients (n = 2688) 
OR (95% CI) P
1 C C 0.8181 1.00 — 0.8224 1.00 — 0.8295 1.00 —
2 C T 0.1139 1.14 (0.99–1.31) 0.066 0.1706 1.10 (0.92–1.32) 0.30 0.1088 1.02 (0.79–1.30) 0.91
3 T T 0.0571 1.18 (0.98–1.42) 0.13 0.0530 1.39 (1.11–1.74) 0.0042 0.0538 1.04 (0.75–1.44) 0.82
4 T C 0.0109 2.21 (1.37–3.56) 0.0011 — — — — — —
Table 5. Overall and ACPA-stratified haplotype association analysis for RA. †Estimates calculated according to 
a dominant model. Minimum haplotype frequency was set at 0.01. P < 0.05 in bold.
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Gene SNP ID Chr.
Effect 
allele
Discovery population 
(n = 604)
Replication DREAM 
registry (n = 882)
Replication DANBIO 
Registry (n = 621) Meta-analysis (n = 2107)
OR (95% CI)∂ P OR (95% CI)∂ P OR (95% CI)∂ P OR (95% CI)∂ P I2
GBP6 rs928655 1 A 1.05 (0.87–1.27) 0.61 0.90 (0.80–1.00) 0.058 ND ND 0.95 (0.82–1.10) 0.52 0.17
IKBKB rs11986055 8 A 0.74 (0.48–1.11) 0.14 0.85 (0.66–1.07) 0.17 0.94 (0.64–1.39) 0.76 0.85 (0.71–1.02) 0.074 0.71
IRF4 rs1050975 6 A 0.95 (0.72–1.24) 0.69 0.99 (0.83–1.17) 0.87 1.24 (0.94–1.65) 0.13 1.03 (0.90–1.18) 0.67 0.33
IRF4 rs12203592 6 T 1.01 (0.77–1.33) 0.93 ND ND ND ND ND ND ND
IRF4 rs1877175 6 T 1.09 (0.90–1.33) 0.37 0.92 (0.82–1.13)* 0.15 0.90 (0.75–1.09) 0.30 0.96 (0.86–1.07) 0.47 0.31
IRF4 rs7768807 6 T 0.86 (0.72–1.03) 0.10 1.04 (0.93–1.16)* 0.52 ND ND 0.96 (0.80–1.15) 0.65 0.08
KLRC1 rs7301582 12 T 1.05 (0.86–1.27) 0.62 1.00 (0.88–1.12) 0.94 0.99 (0.80–1.22) 0.92 1.00 (0.92–1.11) 0.85 0.90
KLRK1 | KLRC4 rs1049174 12 C 1.08 (0.91–1.29) 0.37 0.96 (0.86–1.08) 0.53 1.07 (0.90–1.27) 0.47 1.01 (0.93–1.10) 0.79 0.42
KLRK1 | KLRC4 rs1154831 12 A 0.89 (0.73–1.10) 0.28 1.05 (0.93–1.19)* 0.40 ND ND 0.99 (0.84–1.16) 0.88 0.18
KLRK1 | KLRC4 rs2255336 12 A 1.09 (0.90–1.33) 0.38 1.01 (0.89–1.16) 0.81 ND ND 1.04 (0.93–1.15) 0.54 0.53
LOC105376246 rs2722824 9 A 1.03 (0.86–1.23) 0.77 0.94 (0.85–1.05) 0.32 ND ND 0.96 (0.88–1.05) 0.41 0.39
NFKB1 rs4648110 4 A 1.07 (0.88–1.29) 0.51 1.00 (0.89–1.13)* 0.95 ND ND 1.02 (0.92–1.13) 0.71 0.56
NFKB2 rs11574851 10 T 0.97 (0.73–1.29) 0.83 0.92 (0.72–1.18)* 0.53 0.78 (0.57–1.06) 0.11 0.90 (0.76–1.05) 0.18 0.57
NFKB2 rs12769316 10 T 0.92 (0.75–1.13) 0.43 ND ND 0.86 (0.70–1.06) 0.16 0.89 (0.77–1.03) 0.12 0.65
NFKB2 | PSD rs1056890 10 T 1.22 (1.03–1.44) 0.025 1.08 (0.98–1.19) 0.11 1.31 (1.10–1.57) 0.0030 1.18 (1.05–1.33) 0.0077 0.12
NFKBIB rs3136645 19 C 0.90 (0.73–1.11) 0.34 ND ND ND ND ND ND ND
NLRP3 rs4612666 1 T 1.05 (0.87–1.25) 0.62 1.20 (1.05–1.37)* 0.006 0.96 (0.80–1.14) 0.62 1.08 (0.94–1.23) 0.28 0.13
REL rs13031237 2 T 1.07 (0.91–1.26) 0.40 1.03 (0.94–1.14) 0.49 1.08 (0.92–1.28) 0.36 1.05 (0.97–1.13) 0.21 0.86
REL rs842647 2 A 1.03 (0.86–1.24) 0.72 0.96 (0.87–1.06) 0.45 ND ND 0.98 (0.89–1.06) 0.57 0.51
REL rs13017599 2 A 1.07 (0.91–1.27) 0.41 1.03 (0.94–1.14) 0.50 1.03 (0.86–1.21) 0.78 1.04 (0.96–1.12) 0.33 0.92
RELA rs11820062 11 T 1.07 (0.90–1.26) 0.45 0.92 (0.84–1.01)* 0.081 ND ND 0.98 (0.84–1.13) 0.74 0.12
RELA rs2306365 11 A 0.91 (0.71–1.16) 0.45 1.19 (1.03–1.37) 0.021 ND ND 1.06 (0.82–1.38) 0.66 0.064
RELA rs7119750 11 T 0.93 (0.73–1.18) 0.54 ND ND ND ND ND ND ND
TLR10 rs11096957 4 A 1.00 (0.85–1.19) 0.98 0.99 (0.89–1.09) 0.80 ND ND 0.99 (0.91–1.08) 0.87 0.92
TLR4 rs4986791 9 T 1.15 (0.78–1.70) 0.47 1.18 (0.98–1.41)* 0.077 ND ND 1.18 (1.00–1.39) 0.056 0.91
TLR5 rs5744174 1 C 0.99 (0.83–1.17) 0.89 ND ND ND ND ND ND ND
TLR9 | | TWF2 rs187084 3 T 1.02 (0.86–1.21) 0.81 0.98 (0.88–1.08)* 0.67 ND ND 0.99 (0.91–1.08) 0.83 0.69
TRAF1 | | C5 rs3761847 9 A 1.08 (0.91–1.29) 0.37 1.05 (0.95–1.16) 0.33 ND ND 1.04 (0.96–1.14) 0.35 0.77
Table 6. Meta-analysis for the association of NFKB-related polymorphisms and relative change of DAS28 
score (∆DAS28). Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval. 
A random effect model was assumed for the meta-analysis of both cohorts. ∂Estimates calculated according 
to an additive model of inheritance and adjusted for age, sex and country of origin (or age and sex in the 
replication stages). *Estimates based on imputed genotypes. P < 0.05 in boldface. No significant heterogeneity 
(heterogeneity chi-squared) was observed in any meta-analysis reported above.
Figure 2. Meta-analysis of the association of the NFKB2rs1056890 SNP with response to TNFi [A] and correlation 
with higher levels of IL10 after stimulation of PBMCs (n = 377) with LPS [B]. [A] Association estimates 
according to a random effect model. PMeta = 0.0077. [B] Correlation with IL10 was analysed using genotype 
data of the NFKB2rs1005044 SNP, a marker in strong LD with the rs1056890 (r2 = 1.00).
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Conclusions
In conclusion, this study reports, for the first time, a consistent association of the NFKB2rs11574851 polymorphism 
and NFKB2TT haplotype with an increased risk of developing RA in ACPA-positive subjects. In addition, this 
study suggests a possible role of the NFKB2 locus in the modulation of the response to TNFi. Mechanistically, the 
functional experiments in the 500FG cohort suggested that the effect attributed to the NFKB2 gene in the mod-
ulation of the response to TNFi might be mediated by IL10-mediated immune responses. However, additional 
studies are still warranted to shed light into the biological processes that link NFKB2 SNPs and RA risk and drug 
response.
Data availability
All data used in this project have been meticulously cataloged and archived in the BBMRI-NL data infrastructure 
(https://hfgp.bbmri.nl/) using the MOLGENIS open source platform for scientific data45. This allows flexible data 
querying and download, including sufficiently rich metadata and interfaces for machine processing (R statistics, 
REST API) and using FAIR principles to optimize Findability, Accessibility, Interoperability and Reusability46. 
Genetic data from the discovery and DANBIO populations can be accessed at ftp.genyo.es and data from the 
DREAM registry are available at https://www.synapse.org/#!Synapse:syn3280809/wiki/194735 and https://www.
synapse.org/#!Synapse:syn3280809/wiki/194736.
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